- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04967716
Genetics of Charcot-Marie-Tooth Dystrophy and Related Diseases
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
[Background] Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of the most common hereditary peripheral neuropathy, with a prevalence of about 1/2500-4000. The inheritance mode can be autosomal dominant inheritance, autosomal recessive inheritance, X-linked dominant inheritance and X-linked recessive inheritance. The typical clinical manifestations are progressive, length-dependent weakness and atrophy of the distal limbs, accompanied by hypoesthesia and weakened tendon reflexes. But the generalized peroneal muscular atrophy also includes hereditary motor neuropathy and hereditary sensory neuropathy, which represents the evolution of a disease spectrum from motor nerve to motor sensory nerve and sensory nerve, collectively referred to as CMT and its related diseases. CMT can be divided into demyelinating type (CMT1), axonal type (CMT2) and intermediate type. There are more than 80 kinds of genes discovered so far, and genetic diagnosis plays a vital role in the treatment of peroneal muscular atrophy and genetic counseling.
[Purpose]
- To clarify the gene lineage distribution of CMT genes in CMT patients in my country, draw a frequency map of CMT gene distribution, and assist in determining the genetic diagnosis strategy of CMT diseases;
- Discover new mutations and newly published types of known genes, and perform gene-phenotype correlation analysis
- Perform whole-exome sequencing on some families that have not been clearly diagnosed to find new pathogenic genes or related genes of CMT, so as to enrich the genetic and clinical types of CMT.
[Design] This is a cross-sectional study. All patients will be collected for clinical and electrophysiological data. Patients and families who meet the enrollment criteria will be tested for blood tests. The inspection strategies are as follows: (1) Use MLPA method for PMP22 gene Duplicate or deletion mutation check (charge); (2)) Use high-throughput sequencing method to detect the currently known gene panel (gene panel) (charge); (3) Check the process (1) and (2) Some patients and families whose disease-causing genes have not been detected by the inspection methods are tested by whole-exome sequencing (scientific research, free of charge).
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Xiaoxuan Liu
- Numero di telefono: 13910982101
- Email: zhangys0317@126.com
Backup dei contatti dello studio
- Nome: Xiaoxuan Liu
- Email: zhangys0317@126.com
Luoghi di studio
-
-
-
Beijing, Cina
- Reclutamento
- Peking University Third Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Meet the clinical diagnostic criteria of peroneal muscular atrophy; Sign informed consent
Exclusion Criteria:
- Those who have recently received blood transfusion treatment will not be able to collect blood samples.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Peroneal muscular atrophy
Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of genetic diseases that invade the peripheral nervous system with very high genetic heterogeneity.
It was proposed by Charcot, Marie of France and Tooth of the United Kingdom in 1886.
The prevalence is about 1/2500-4000.
It is the most common hereditary peripheral neuropathy.
Inheritance includes all forms of Mendelian inheritance.
The typical clinical manifestations are progressive, length-dependent limb weakness and atrophy, accompanied by hypoesthesia and weakened tendon reflexes.
|
Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation.
No fasting is required before blood draw, and there is no time limit.
Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital.
The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
allele frequency of CMT genes
Lasso di tempo: 1 month
|
Observed values of allele frequency of CMT genes
|
1 month
|
|
genotype frequency of CMT genes
Lasso di tempo: 1 month
|
Observed values genotype frequency of CMT genes
|
1 month
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Xiaoxuan Liu, Peking University Third Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso
- Manifestazioni neurologiche
- Anomalie congenite
- Malattie genetiche, congenite
- Malattie neuromuscolari
- Malattie Neurodegenerative
- Malattie del sistema nervoso periferico
- Manifestazioni neuromuscolari
- Condizioni patologiche, anatomiche
- Malattie Eredodegenerative, Sistema Nervoso
- Atrofia
- Malformazioni del sistema nervoso
- Polineuropatie
- Atrofia muscolare
- Sindromi da compressione nervosa
- Malattia di Charcot-Marie-Tooth
- Neuropatia sensoriale e motoria ereditaria
Altri numeri di identificazione dello studio
- M2018206
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .